Nadya Belenky1, Brian W Pence1, Stephen R Cole1, Stacie B Dusetzina2,3, Andrew Edmonds1, Jonathan Oberlander3,4, Michael W Plankey5, Adebola Adedimeji6, Tracey E Wilson7, Jennifer Cohen8, Mardge H Cohen9, Joel E Milam10, Elizabeth T Golub11, Adaora A Adimora1,12. 1. Departments of Epidemiology. 2. Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy. 3. Health Policy and Management, Gillings School of Global Public Health. 4. Department of Social Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC. 5. Department of Medicine, Division of Infectious Diseases and Travel Medicine, Georgetown University, Washington, DC. 6. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx. 7. Department of Community Health Sciences, School of Public Health, Downstate Medical Center, State University of New York, Brooklyn, NY. 8. Department of Clinical Pharmacy, University of California, San Francisco. 9. Departments of Medicine, Stroger Hospital and Rush University, Chicago, IL. 10. Department of Preventive Medicine, University of Southern California, Los Angeles, CA. 11. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 12. School of Medicine, Division of Infectious Diseases, The University of North Carolina at Chapel Hill, NC.
Abstract
BACKGROUND: The implementation of Medicare part D on January 1, 2006 required all adults who were dually enrolled in Medicaid and Medicare (dual eligibles) to transition prescription drug coverage from Medicaid to Medicare part D. Changes in payment systems and utilization management along with the loss of Medicaid protections had the potential to disrupt medication access, with uncertain consequences for dual eligibles with human immunodeficiency virus (HIV) who rely on consistent prescription coverage to suppress their HIV viral load (VL). OBJECTIVE: To estimate the effect of Medicare part D on self-reported out-of-pocket prescription drug spending, AIDS Drug Assistance Program (ADAP) use, antiretroviral adherence, and HIV VL suppression among dual eligibles with HIV. METHODS: Using 2003-2008 data from the Women's Interagency HIV Study, we created a propensity score-matched cohort and used a difference-in-differences approach to compare dual eligibles' outcomes pre-Medicare and post-Medicare part D to those enrolled in Medicaid alone. RESULTS: Transition to Medicare part D was associated with a sharp increase in the proportion of dual eligibles with self-reported out-of-pocket prescription drug costs, followed by an increase in ADAP use. Despite the increase in out-of-pocket costs, both adherence and HIV VL suppression remained stable. CONCLUSIONS: Medicare part D was associated with increased out-of-pocket spending, although the increased spending did not seem to compromise antiretroviral therapy adherence or HIV VL suppression. It is possible that increased ADAP use mitigated the increase in out-of-pocket spending, suggesting successful coordination between Medicare part D and ADAP as well as the vital role of ADAP during insurance transitions.
BACKGROUND: The implementation of Medicare part D on January 1, 2006 required all adults who were dually enrolled in Medicaid and Medicare (dual eligibles) to transition prescription drug coverage from Medicaid to Medicare part D. Changes in payment systems and utilization management along with the loss of Medicaid protections had the potential to disrupt medication access, with uncertain consequences for dual eligibles with human immunodeficiency virus (HIV) who rely on consistent prescription coverage to suppress their HIV viral load (VL). OBJECTIVE: To estimate the effect of Medicare part D on self-reported out-of-pocket prescription drug spending, AIDS Drug Assistance Program (ADAP) use, antiretroviral adherence, and HIV VL suppression among dual eligibles with HIV. METHODS: Using 2003-2008 data from the Women's Interagency HIV Study, we created a propensity score-matched cohort and used a difference-in-differences approach to compare dual eligibles' outcomes pre-Medicare and post-Medicare part D to those enrolled in Medicaid alone. RESULTS: Transition to Medicare part D was associated with a sharp increase in the proportion of dual eligibles with self-reported out-of-pocket prescription drug costs, followed by an increase in ADAP use. Despite the increase in out-of-pocket costs, both adherence and HIV VL suppression remained stable. CONCLUSIONS: Medicare part D was associated with increased out-of-pocket spending, although the increased spending did not seem to compromise antiretroviral therapy adherence or HIV VL suppression. It is possible that increased ADAP use mitigated the increase in out-of-pocket spending, suggesting successful coordination between Medicare part D and ADAP as well as the vital role of ADAP during insurance transitions.
Authors: Thomas Yi; Jennifer Cocohoba; Mardge Cohen; Kathryn Anastos; Jack A DeHovitz; Naoko Kono; David B Hanna; Nancy A Hessol Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Christina Ludema; Stephen R Cole; Joseph J Eron; Andrew Edmonds; G Mark Holmes; Kathryn Anastos; Jennifer Cocohoba; Mardge Cohen; Hannah L F Cooper; Elizabeth T Golub; Seble Kassaye; Deborah Konkle-Parker; Lisa Metsch; Joel Milam; Tracey E Wilson; Adaora A Adimora Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: C Holkmann Olsen; A Mocroft; O Kirk; S Vella; A Blaxhult; N Clumeck; M Fisher; C Katlama; A N Phillips; J D Lundgren Journal: HIV Med Date: 2007-03 Impact factor: 3.180
Authors: Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander Journal: Ann Intern Med Date: 2008-01-07 Impact factor: 25.391
Authors: Rob McCarney; James Warner; Steve Iliffe; Robbert van Haselen; Mark Griffin; Peter Fisher Journal: BMC Med Res Methodol Date: 2007-07-03 Impact factor: 4.615
Authors: Derek D Satre; Sujaya Parthasarathy; Michael J Silverberg; Michael Horberg; Kelly C Young-Wolff; Emily C Williams; Paul Volberding; Cynthia I Campbell Journal: BMC Health Serv Res Date: 2020-11-11 Impact factor: 2.655